Report data from the phase 2 pilot EF-31 trial in gastric cancer
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 31 Dec 2021
- Delivered
- June 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Data from phase 2 pilot EF-31 trial in gastric cancer (2021)”
What we found
Evidence strength A What the grades mean
The company did not report the EF-31 trial data in 2021 as originally committed; the results were announced in June 2022.
-
A NovoCure Ltd 10-Q filed 2022-10-27
“In June 2022, we announced results of the phase 2 pilot EF-31 study evaluating the use of TTFields together with standard-of-care” ✓ confirmed on the page
Market reaction: the shares moved +3.3% against the S&P 500 over the three sessions around the disclosure (26 Oct 2022 to 31 Oct 2022). What this measures
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- EF-31 trial data
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you NovoCure Ltd? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-NVCR-021849 · Corrections policy